Literature DB >> 25581451

Improving the quality of end-of-life discussions.

Jeff Myers1.   

Abstract

PURPOSE OF REVIEW: This article provides an update on the recent research and evidence regarding quality in end-of-life (EOL) discussions with a focus on the care of a person with cancer. RECENT
FINDINGS: Clinicians have the challenging task of customizing the information exchange that occurs during an EOL discussion. Patients identify important stipulations that accompany a desire for frank EOL discussions. These include timing of the discussion, ensuring evaluation of readiness to engage in the EOL discussion, and being invited to participate. The timing of an EOL discussion is likely to be more important than the setting in which an EOL discussion occurs. Less than 1 month prior to a person's death is likely to be an inadequate amount of time to allow a patient to consider and reflect on his or her EOL preferences. Among those admitted to the hospital, delay in the timing of EOL discussions carries the risk of losing decision-making capacity.
SUMMARY: There is greater use of quality metrics as patient outcomes among studies examining EOL discussions. System-wide approaches to improving EOL discussions should include standardized documentation templates that are widely accessible in electronic medical records.

Entities:  

Mesh:

Year:  2015        PMID: 25581451     DOI: 10.1097/SPC.0000000000000108

Source DB:  PubMed          Journal:  Curr Opin Support Palliat Care        ISSN: 1751-4258            Impact factor:   2.302


  2 in total

1.  End-of-life discussions reduce the utilization of life-sustaining treatments during the last three months of life in cancer patients.

Authors:  Shang-Yih Chan; Yun-Ju Lai; Yu-Yen Chen; Chu-Chieh Chen; Shuo-Ju Chiang; Yi-Fan Tsai; Li-Fei Hsu; Pei-Hung Chuang; Yung-Feng Yen
Journal:  Sci Rep       Date:  2022-05-06       Impact factor: 4.996

2.  Is there lower utilisation of hospice care services during end-of-life care for people living with HIV? A population-based cohort study.

Authors:  Shang-Yih Chan; Yun-Ju Lai; Ming-Chung Ko; Yu-Yen Chen; Yi-Fan Tsai; Li-Fei Hsu; Po-Wen Ku; Li-Jung Chen; Pei-Hung Chuang; Chu-Chieh Chen; Yung-Feng Yen
Journal:  BMJ Open       Date:  2022-03-14       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.